AMGN:NASDAQAmgen Inc. Analysis

Amgen (AMGN) is trading at $376.97, just above its 20‑day SMA of 375.80 and comfortably over the 50‑day SMA of 353.60, indicating a short‑term bullish bias. However, the MACD histogram is negative (‑2.27) and the signal line is bearish, suggesting momentum may be weakening as the price approaches the resistance level of $391.29. The RSI sits at 55.6, well within the neutral zone, and the stock sits on a solid support of $361, giving it a modest technical cushion.
Fundamentally, AMGN delivers strong profitability with a gross margin of 70.8% and an operating margin of 30.5%, while revenue is growing at 8.6% YoY. The forward PE of 16.2 and a dividend yield of 2.73% (payout ratio 66.9%) provide income appeal, yet the DCF‑derived fair value of $191.79 implies the market is pricing in a significant premium, reflected in an overvaluation relative to peers (PE 26.5 vs industry 25.4). The company carries a high debt‑to‑equity ratio of 640, but generates robust free cash flow of $7.5 bn, supporting dividend sustainability. Overall sentiment is bullish, with a Fear & Greed Index at “Extreme Greed,” but the valuation gap and regulatory exposure temper enthusiasm.